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Abstract: Hepcidin is the master regulator of systemic iron bioavailability in humans.  
This review examines primary research articles that assessed hepcidin during pregnancy 
and postpartum and report its relationship to maternal and infant iron status and birth 
outcomes; areas for future research are also discussed. A systematic search of the databases 
Medline and Cumulative Index to Nursing and Allied Health returned 16 primary research 
articles including 10 human and six animal studies. Collectively, the results indicate that 
hepcidin is lower during pregnancy than in a non-pregnant state, presumably to ensure 
greater iron bioavailability to the mother and fetus. Pregnant women with undetectable 
serum hepcidin transferred a greater quantity of maternally ingested iron to their fetus 
compared to women with detectable hepcidin, indicating that maternal hepcidin in part 
determines the iron bioavailability to the fetus. However, inflammatory states, including 
preeclampsia, malaria infection, and obesity were associated with higher hepcidin during 
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pregnancy compared to healthy controls, suggesting that maternal and fetal iron 
bioavailability could be compromised in such conditions. Future studies should examine 
the relative contribution of maternal versus fetal hepcidin to the control of placental iron 
transfer as well as optimizing maternal and fetal iron bioavailability in pregnancies 
complicated by inflammation. 
Keywords: hepcidin; pregnancy; iron regulation; inflammation 
 
1. Introduction 
Iron is essential for many metabolic processes, including oxygen transport and regulation of cell growth 
and differentiation [1,2]. Iron deficiency most prominently causes anemia, limiting oxygen delivery to 
cells, but iron deficiency can also cause dysfunction of the epithelia, muscle, and the nervous system [3]. 
On the other hand, excess amounts of iron in cells and tissues can result in tissue toxicity [1,4]. 
Iron requirements increase nearly 10-fold during pregnancy from 0.8 mg/day in the first trimester to 
7.5 mg/day in the third trimester (Figure 1) [5]. During pregnancy, iron is needed to support placental 
and fetal growth [6], sustain the increase in maternal red blood cell mass [7], and compensate for blood 
losses that will occur during delivery [8]. The Recommended Dietary Allowance (RDA) for iron 
increases from 18 mg/day for non-pregnant females to 27 mg/day during pregnancy [2]. Importantly, the 
RDA does not take into account varying bioavailability of iron among individuals. The median dietary 
iron intake among pregnant women is approximately 15 mg/day [2], an amount insufficient to support 
the increased demand during pregnancy. Therefore, many major health organizations recommend iron 
supplementation throughout pregnancy. The Centers for Disease Control and Prevention recommends 
routine low-dose iron supplementation (30 mg/day) for all pregnant women [9] and the Institute of 
Medicine also supports iron supplementation during pregnancy [2]. 
Figure 1. Estimated daily iron requirements during pregnancy in a 55-kg woman [5].  
(with permission to publish photo from The American Journal of Clinical Nutrition). 
 
Iron is important for early placental development, which maintains pregnancy and provides 
nutrients and oxygen to the developing fetus [10–14]. Iron deficiency can adversely impact birth 
outcomes and result in preterm birth and low birth weight [15–19]. The mechanisms by which iron 
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deficiency may affect birth outcomes are unknown, but the effects of hypoxia, oxidative stress, and 
increased risk of infection have been proposed as potential pathways [20]. Hypoxia, as a result of iron 
deficiency, could initiate a stress response, including the release of corticotropin-releasing hormone 
from the placenta and increased production of cortisol by the fetus, both of which are associated with 
increased risk of preterm birth [21,22]. Iron deficiency is associated with increased oxidative stress [23] 
and this could damage the placenta during early development [24–26]. Iron deficiency can also 
negatively impact the immune response [27] and thus increase the risk of infection during pregnancy. 
Our current understanding of the mechanism by which iron is transferred from mother to fetus is 
depicted in Figure 2 [28]. Iron (Fe) is carried in the maternal blood bound to transferrin (Tf).  
The syncytiotrophoblast, the epithelium on placental villi that interfaces with maternal blood and 
participates in nutrient exchange, contains Tf receptors (TfR) on the surface facing maternal circulation. 
The binding of Fe-Tf to TfR depends on the pH levels, having a greater affinity at pH 7.4 [29].  
After binding, the Fe-Tf/TfR complex is endocytosed, and the vesicle is acidified through activation of 
hydrogen pumps [30]. The lower pH allows the dissociation of iron from the maternal Tf. Once released, 
iron is actively transported out of the vesicle into the cytosol where it is used for cellular processes, 
stored in ferritin or exported into fetal circulation. The TfR and Tf then return to the maternal surface 
of syncytiotrophoblast where Tf is released into the maternal circulation and the cycle repeats [30]. 
Iron is exported from the basolateral side of the synctiotrophoblast into fetal circulation by ferroportin 
(Fpn) [30], the only know iron exporter in vertebrates. In fact, knockout of Fpn in mice causes 
embryonic lethality due to severe iron deficiency of the embryo [31]. Following iron export through 
Fpn, a ferroxidase (possibly zyklopen) [32] oxidizes iron so it can be loaded onto fetal transferrin. 
In the last decade, there has been a revolution in our understanding of systemic iron homeostasis. 
Hepcidin is a peptide hormone that functions as both the homeostatic regulator of systemic iron 
metabolism and a mediator of host defense. Sensing of circulating iron and iron stores is thought to 
occur in the liver, which is the primary site of hepcidin production and secretion [33–35].  
Hepcidin production can be assessed by measuring liver hepcidin mRNA levels (in animal models) or 
by measuring hepcidin peptide in the serum or plasma (in humans and mice) [36]. Circulating hepcidin 
is rapidly excreted through the kidneys (half-life in circulation is several minutes), and the peptide can 
also be measured in urine. Because hepcidin production is predominantly regulated at the transcriptional 
level, hepcidin mRNA and protein levels show high correlation. Hepcidin controls the efflux of iron 
into plasma by regulating Fpn (Figure 3). In addition to the placenta, Fpn is located on tissues  
that actively export iron including intestinal enterocytes, reticuloendothelial macrophages, and 
hepatocytes [33]. Hepcidin triggers Fpn degradation, reducing iron flux from these tissues thereby 
decreasing plasma iron concentrations and systemic iron bioavailability [34,37]. Hepcidin production 
by the liver is simultaneously regulated by circulating and stored iron, erythropoietic activity, and 
inflammation [36]. Therefore, at any time, hepcidin expression is determined by the interplay of these 
pathways and the relative strength of each of the individual signals [38]. When body iron levels are 
elevated or inflammation or infection is present, liver hepcidin production is increased resulting in 
diminished Fpn expression. Conversely, when body iron levels are depleted or anemia or hypoxia 
exists, hepcidin expression is reduced, allowing for increased dietary iron absorption and mobilization 
from body stores via active Fpn. Furthermore, hepcidin concentrations markedly influence iron 
absorption and can affect the efficacy of iron repletion via supplemental or dietary sources [39]. 
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Therefore, given that iron accessibility is critical throughout pregnancy for both the mother and 
developing fetus, and hepcidin regulates systemic iron bioavailability, it is important to evaluate 
hepcidin concentrations in both uncomplicated and complicated pregnancies and throughout gestation. 
The purpose of this review is to examine primary human and animal research studies that assessed 
hepcidin during pregnancy and postpartum, discuss relationship with maternal and fetal iron status, 
determine gaps in the literature, and suggest future areas for research. 
Figure 2. Mechanism of iron transfer across the placenta. The syncytiotrophoblast takes up 
iron-transferrin from maternal circulation via the transferrin receptors (TfR) cycle. After 
the holo-Tf/TfR complex is endocytosed, and iron is released from the complex in the acidifed 
endosome, iron is transported into the cytosol likely by the divalent metal transporter-1 
(DMT-1). Iron is exported from the basolateral side of the synctiotrophoblast into fetal 
circulation by ferroportin (Ireg1). A ferroxidase (possibly zyklopen) oxidizes iron so it can be 
loaded onto fetal transferrin [28]. (with permission to publish photo from Nutrition Reviews). 
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Figure 3. Hepcidin-ferroportin (Fpn) interaction determines the flow of iron into  
plasma. Hepcidin concentration is in turn regulated by iron, erythropoietic activity, and  
inflammation [40]. (with permission to publish photo from Blood: Journal of the American 
Society of Hematology). 
 
2. Methods 
The databases Pubmed and Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
were searched with the terms: “pregnancy”, “hepcidin” and “iron”. Studies were considered for this 
review if hepcidin-25, the bioactive form of hepcidin, was measured in urine, serum or plasma, or if 
tissue-level gene expression (mRNA) was examined. Studies that measured pro-hepcidin were 
excluded because this metabolite is biologically inactive [41], does not correlate with serum hepcidin 
concentrations [42], nor does it demonstrate expected correlations with iron or inflammatory 
parameters [42,43]. Two other studies that used a commercially available hepcidin enzyme-linked 
immunosorbent assay (ELISA) were also excluded [44,45] because the assay was not clinically validated 
and does not correlate with mass spectrometric measurements [46]. There was no language restrictions 
included in the search, however, all the articles retrieved were written in English. The references for 
each primary research article were crosschecked to ensure that all studies were included. 
Data extracted from the human studies included study design, sample size, maternal health status, 
presence of obstetrical complications, gestational age, study location, maternal age, body mass index 
(BMI), race/ethnicity, inclusion and exclusion criteria, biological sample type, timing of specimen 
collection, method used to measure hepcidin, maternal and fetal hepcidin concentrations, and associations 
between hepcidin with clinical and biochemical parameters. Data extracted from the animal studies 
included study design, sample size, animal type, experimental groups, gestational age, diet, biological 
sample type, timing of specimen collection, and assay used to measure hepcidin, and maternal and 
fetal hepcidin concentrations. 
3. Results and Discussion 
Hepcidin is the systemic regulator of iron metabolism, and iron availability is critical during 
pregnancy for both mother and fetus. This review reveals a significant paucity of studies assessing 
hepcidin during pregnancy. Ten human [47–56] and six animal studies [57–62] met the inclusion 
criteria with findings reported in Table 1. 
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Table 1. Studies included in review of hepcidin values in pregnancy. 
Author Design Sample Hepcidin Main Study Findings 
Human Studies 
Finkenstedt  
et al. (2012) 
[54] 
Longitudinal, 
prospective 
 n = 42 
 Health status: 38 healthy and 4 with 
complications  
(preeclampsia: n = 1, GDM: n = 1,  
C/S: n = 1, preeclampsia and GDM: n = 1). 
 Location: NDR 
 Maternal age (years): 26.4 (range 17–40) 
 BMI (kg/m2): NDR 
 Parity: primigravida: n = 7, previous pregnancy 
mean = 1.6 
 Race/Ethnicity: NDR 
 Inclusion/Exclusion criteria: NDR 
 Sample: Maternal serum 
 Timing: 1st and 3rd trimester  
(n = 42); 2nd trimester (n = 12) 
 Method: SELDI time-of-flight mass 
spectrometry [63] 
 Hepcidin reference range: average  
for healthy women 50 ng/mL  
(range < 10–200 ng/mL) 
 Maternal serum hepcidin:  
1st trimester: median = 16 ng/mL (4–97);  
2nd trimester: median = 11 ng/mL (6–36);  
3rd trimester: median = 9.5 ng/mL (1–43), p < 0.001 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters:  
Serum iron (r = 0.391, p < 0.001),  
ferritin (r = 0.573, p < 0.001), Tsat (r = 0.457; p < 0.001),  
sHJV (r = −0.231; p = 0.025), EPO (r = −0.308; p = 0.002). 
van Santen  
et al. (2013) 
[55] 
Longitudinal, 
prospective 
 n = 31 
 Health status: healthy except for complications 
in 3 (10%) 
 Location: The Netherlands 
 Maternal age (years): 33.1 ± 5.4 
 BMI (kg/m2): NDR 
 Parity 0 = 13 (42%), Parity 1 = 11 (36%),  
Parity ≥ 2 = 7 (23%) 
 Race/Ethnicity: Northern European  
(n = 29) or Southeast Asian (n = 2) 
 Inclusion criteria: Normal hematologic  
blood count, renal function and liver enzymes 
at first visit 
 Sample: Maternal serum 
 Timing: 9–15, 19–25 and 29–35 
weeks gestation; within 24 h 
postpartum; 6 weeks post-delivery 
 Method: combination of weak 
cation exchange chromatography 
and time-of-flight mass 
spectrometry [64] 
 lower limit of detection: 0.25 nmol/L 
 Hepcidin reference range: median  
2.0 nmol/L (range < 0.5–12.3 nmol/L) 
 Maternal serum hepcidin:  
15–19 weeks gestation: 1.85 nmol/L (1.10–4.10);  
20–25 weeks gestation: 0.25 nmol/L (0.25–1.20);  
29–35 weeks gestation: 0.25 (0.25–0.25, undetectable);  
24 h postpartum: 3.0 nmol/L (0.66–9.22);  
6 weeks post-delivery: 1.35 nmol/L (0.73–2.40) 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: Serum ferritin (r2 = 0.516, p < 0.0001), serum iron 
(r2 = 0.1, p = ns), Hgb (r2 = 0.275, p = 0.015), TIBC  
(r2 = −0.483, p < 0.0001), sTfR (r2 = −0.293, p = 0.008),  
sTfR-index (r2 = −0.452, p < 0.001), and Tsat (r2 = 0.243,  
p = 0.029), CRP (r2 = 0.322, p = ns) 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Human Studies 
Dao et al. 
(2013) [56] 
Longitudinal, 
prospective 
 n = 30 
 Health status: (n = 15 Lean; n = 15 Obese) 
GDM (Obese, n = 1; Lean, n = 1) 
 OB complication: C/S (Obese, n = 7;  
Lean, n = 4) 
 Location: Boston, MA, USA 
 Maternal age (years): Obese: 30.0 ± 3.9;  
lean 32.1 ± 5.8 
 BMI (kg/m2): Obese = 38.6 ± 7.0;  
Lean = 22.8 ± 1.5 
 Parity: NDR 
 Race/Ethnicity: Obese: Caucasian n = 6;  
AA n = 6; Hispanic n = 2; Asian n = 1;  
Lean: Caucasian n = 9; AA n = 0;  
Hispanic n = 5; Asian n = 1 
 Exclusion Criteria: type 2 diabetes, 
preeclampsia, autoimmune disease,  
acute infection, premature membrane  
rupture and chorioamnionitis 
 Sample: Maternal serum and  
cord blood 
 Timing: 24–28 weeks gestation 
(maternal sample); childbirth  
(cord blood) 
 Method: ELISA (Bachem Group, 
Torrance, CA, USA) 
 Hepcidin reference range: NDR 
 Maternal serum hepcidin: (24–28 weeks gestation): Obese:  
13.5 ± 9.0 ng/mL; Lean: 5.1 ± 2.7 ng/mL (p < 0.01).  
Correlated with maternal BMI: r = 0.4, p = 0.04 
 Maternal inflammatory status (24–28 weeks gestation):  
CRP: Obese: 14.3 (IQR: 11.5) mg/L; Lean: 5.0 (IQR: 4.4) mg/L 
(p < 0.01) CRP: Obese: 14.3 (IQR: 11.5) mg/L;  
Lean: 5.0 (IQR: 4.4) mg/L (p < 0.01) 
 Maternal iron status (24–28 weeks gestation) (extrapolated 
from Figure 1): Serum iron: Obese: 60 μg/dL; Lean: 78 μg/dL  
Tsat: Obese: 15% Lean: 19% 
 Cord blood hepcidin (Childbirth) (extrapolated from Figure 1):  
Obese: 125 ng/mL; Lean: 120 ng/mL 
 Cord blood iron status parameters Serum iron: Obese:  
97.3 ± 29.9 μg/dL; Lean: 147.7 ± 21.7 μg/dL (p < 0.01);  
Tsat: Obese: 39.6%; Lean: 63.5% (p = 0.01) 
 Correlations of maternal parameters and cord blood iron status 
markers: Maternal BMI and cord blood iron: r = −0.8, p = 0.002;  
Maternal BMI and cord blood Tsat: r = −0.7, p = 0.009;  
Log maternal hepcidin and cord blood iron: r = −0.6, p = 0.02; 
Log maternal hepcidin and cord blood Tsat: r = −0.6, p = 0.02 
Gyarmati  
et al. (2011) 
[53] 
Longitudinal, 
prospective 
 n = 38 
 Health status: healthy; elective C/S n = 13 
 Location: Hungary 
 Maternal age: NDR 
 BMI: NDR 
 Parity: NDR 
 Race/ethnicity: NDR 
 Exclusion criteria: presence of infection, 
multiple birth, and any known OB complication 
 Sample: Maternal serum 
 Timing: median 40 (39–41) weeks 
gestation; at first contraction for 
vaginal delivery, or before 
anesthesia for elective C/S, and then 
3 days PP for all 
 Method: mass spectrometry [50] 
 Hepcidin reference range: NDR 
 Maternal serum hepcidin: Vaginal: before birth 2.52 ng/mL 
(2.07–3.1); 3 days PP 7.36 ng/mL(6.34–8.91) (p < 0.001);  
Elective caesarian delivery: before birth 2.83 ng/mL  
(2.53–3.87); 3 days PP 17.5 ng/mL (13.5–18.9) (p < 0.001) 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: NDR; no significant correlation with iron, ferritin 
and IL-6. 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Human Studies 
van Santen  
et al. (2011) 
[51] 
Cross-sectional, 
retrospective 
 n = 69 
 Health status: stratified by group:  
1. no placental malaria and no anemia (n = 21) 
2. no placental malaria and anemia (n = 18) 
3. placental malaria and no anemia (n = 16) 
4. placental malaria and anemia (n = 14). 
 Location: Gabon 
 Maternal age (years): range 16–19 
 BMI (kg/m2): NDR 
 Parity: primigravid 
 Race/Ethnicity: NDR 
 Exclusion criteria: Primigravid without 
peripheral parasitemia, live singleton birth,  
no signs or symptoms of systemic infection 
 Sample: Maternal plasma and  
cord blood 
 Timing: childbirth 
 Method: combination of weak 
cation-exchange chromatography 
and time-of-flight mass spectrometry 
 Hepcidin reference range:  
4.2 nmol/L (0.5–13.9) nmol/L [65] 
 Maternal plasma hepcidin (Childbirth):  
 group 1 = 4.2 (nmol/L) (1.6–8.0) 
 group 2 = 2.8 (nmol/L) (0.5–13.1) 
 group 3 = 4.2 (nmol/L) (2.0–8.1) 
 group 4 = 3.2 (nmol/L) (0.9–5.0) p = 0.70 
 Cord blood hepcidin (Childbirth):  
 group 1 = 4.5 (nmol/L) (2.8–6.8) 
 group 2 = 5.5 (nmol/L) (2.4–9.5) 
 group 3 = 3.7 (nmol/L) (3.0–6.9) 
 group 4 = 4.4 (nmol/L) (1.8–6.5) p = 0.33 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: NDR 
Young et al. 
(2012) [52] 
Correlational, 
cross-sectional, 
prospective 
 n = 19 
 Health status: healthy 
 Location: Rochester, NY, USA 
 Maternal age (years): mean = 19.0 ± 2.9  
(range 16–32) 
 BMI (kg/m2): pre-pregnancy 24.7 [7.0]  
(20.7–43.6); delivery BMI: 30.4 [7.1]  
(24.4–47.5) 
 Parity: mean = 0 ± 0.9 (0–3) 
 Race/Ethnicity: African American 53%, 
Caucasian 47% 
 Inclusion criteria: Healthy, nonsmoking, 
uncomplicated pregnancy 
 Exclusion criteria: gestational diabetes, 
underlying malabsorption, or medical problems 
that affect Fe homeostasis 
 Sample: Maternal serum and  
cord blood 
 Timing: mean = 39.9 ± 1.6 weeks 
(36–41.6) gestation; childbirth 
(maternal sample collected  
at admission) 
 Method: ELISA 
 Hepcidin reference range:  
median = 65 ng/mL (5%–95% range 
17 to 286) [66] 
 Maternal serum hepcidin (Childbirth):  
Median [SD] = 9.30 μg/L [50.1] 
 Cord blood hepcidin (Childbirth): Median [SD] = 61.7 μg/L 
[77.0], p < 0.05 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: ferritin (μg/L) (r2 = 0.59, p = 0.0001), TBI (mg/kg) 
(r2 = 0.59, p = 0.0001), Hgb (g/L) (r2 = 0.31, p = 0.01) and  
TfR (mg/L) (r2 = 0.31, p = 0.01)] 
 Correlations of cord blood hepcidin with neonatal iron and 
inflammatory parameters: ferritin (r2 = 0.60, p < 0.0001) and 
TBI (r2 = 0.60, p = 0.0001) Maternal serum hepcidin did not 
significantly correlate with neonatal serum hepcidin. Pregnant 
women with undetectable levels of serum hepcidin transferred a 
greater quantity of the maternally ingested 57Fe-nonheme or 
58Fe-heme iron to their fetus compared to women with 
detectable levels of serum hepcidin (p = 0.003 and 0.002) 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Human Studies 
Rehu et al. 
(2010) [48] 
Cross-sectional, 
prospective, 
correlational 
 n = 191 
 Health status: vaginal delivery: n = 147;  
elective C/S: n = 24; emergency C/S: n = 20; 
gestational diabetes mellitus: n = 23 gestational 
hypertension: n = 6; preeclampsia: n = 5; liver 
dysfunction: n = 2; three groups: 1. iron-restricted 
erythropoiesis; 2. sufficient iron for erythropoiesis, 
but low iron stores; 3. normal iron stores and 
sufficient iron for erythropoiesis 
 Location: Finland 
 Maternal age (years): median = 28 (range 17–41) 
 BMI (kg/m2): NDR 
 Parity: NDR 
 Race/Ethnicity: NDR 
 Inclusion/Exclusion criteria: NDR 
 Sample: Maternal serum and  
cord blood 
 Timing: median = 40 + 1 weeks 
(37–42) gestation; selected at time 
of delivery <24 h before delivery 
 Method: ELISA 
 Hepcidin reference range: median 
65 ng/mL 5%–95% range 17  
to 286 [66] 
 Maternal serum hepcidin (Childbirth): Overall geometric  
mean = 12.4 ng/mL (95% CI = 10.5–14.6); vaginal geometric 
mean = 13.6 (95% CI = 11.0–17.0); emergency CS geometric 
mean = 15.9 (95% CI = 8.8–28.7); elective CS geometric mean 
= 5.5 (95% CI = 3.2–9.5), significantly lower than vaginal or 
emergency CS; iron-restricted erythropoiesis = 3.8 ng/mL  
(1.5–9.6); low iron stores = 6.7 ng/mL (4.2–10.6); normal iron 
stores = 15.2 ng/mL (11.1–20.7), p = 0.002 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: CRP (r = 0.285, p < 0.001) 
 Cord blood hepcidin (Childbirth):  
geometric mean = 71.6 ng/mL (95% CI = 60.8–84.4),  
p < 0.001; None of the maternal measurements were associated 
with the cord blood hepcidin 
Toldi et al. 
(2010) [50] 
Cross-sectional, 
descriptive 
 n = 67 
 Health status: 30 preeclamptic and 37 healthy 
 Location: Hungary 
 Maternal age (years): median = 30 
 BMI (kg/m2): NDR 
 Parity: NDR 
 Race/Ethnicity: NDR 
 Inclusion/Exclusion criteria: not reported; 
routine perinatal oral iron supplementation:  
all participants. 
 Sample: Maternal plasma 
 Timing: 24–40 weeks gestation; 
preeclamptic median = 36.5  
(24–40) weeks gestation; healthy 
median = 36 (28–39) weeks gestation 
 Method: mass spectrometry  
(LC-MS/MS) [36] 
 Maternal plasma hepcidin 24–40 weeks gestation:Preeclampsia: 
5.68 ng/mL (0.72–9.25) Healthy: 3.74 ng/mL (0.73–8.14)  
(p = 0.003) 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: NDR 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Human Studies 
Schulze  
et al. (2008) 
[49] 
Correlational, 
cross sectional 
prospective. 
 n = 190 
 Health status: purposive sampling of women 
with iron deficiency 
 Location: Bangladesh 
 Maternal age: mean = 21.9 (17.5–25) years 
 BMI (kg/m2): NDR 
 Parity: 48% primigravida; 52% multigravida 
 Race/Ethnicity: NDR 
 Inclusion/Exclusion criteria: not reported 
 Sample: Maternal urine 
 Timing: mean (SD) = 12 (8–14) 
weeks gestation; following 
pregnancy confirmation 
 Method: surface-enhanced laser 
desorption/ionization time-of-flight 
mass spectrometry 
 Hepcidin reference range:  
0.09–2.97 [67] 
 Maternal urine hepcidin 8-14 weeks gestation: median = 2.35 
(intensity/mmol creatinine) (0.51–7.22) 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: ferritin (μg/L) (r = 0.33, p < 0.001) & TfR index 
(TfR/log ferritin) (r = −0.22, p = 0.007); no correlation with 
soluble TfR, hemoglobin, EPO; log AGP (mg/dL) (r = 0.20,  
p = 0.01); no correlation CRP 
Howard  
et al. (2007) 
[47] 
Correlational, 
cross-sectional, 
prospective 
 n = 31 
 Health status: + Plasmodium Falciparum malaria 
 Location: Ghana 
 Maternal age (years): mean = 24.4 
 BMI (kg/m2): NDR 
 Parity: NDR 
 Race/Ethnicity: NDR 
 Inclusion criteria: diagnosed with P. 
Falciparum malaria, not admitted for 
transfusion, had a hemoglobin level >50 g/L, 
and no cerebral malaria 
 Sample: Maternal urine 
 Timing: NDR 
 Method: time-of-flight mass 
spectrometry 
 Hepcidin reference range: 0.09–2.97 
intensity/mmol creatinine [67] 
 Maternal urine hepcidin: mean = 0.7 (intensity/mmolcreatinine) 
(0.2, 5.9) 
 Correlations of maternal hepcidin with iron and inflammatory 
parameters: not associated with hemoglobin or anemia, but 90% 
of women were anemic; log parasitemia positively associated  
(β = 0.218; CI = 0.043–0.392, p = 0.016) 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Animal Studies 
Cornock  
et al. (2013) 
[61] 
Prospective,  
cross-sectional 
 n = 40 
 Animal: virgin Wistar and Rowett Hooded 
Lister rats 
 Age: NDR 
 Diet: Dams fed either 
1. Control iron (50 mg/kg) 
2. Low iron (7.5 mg/kg) 
 Sample: maternal and fetal liver 
 Timing: day 21of gestation, 
placentas and livers dissected  
and frozen 
 Method: mRNA by real-time RT-PCR 
 Maternal liver hepcidin: mRNA hepcidin expression decreased 
in rats fed low iron diet (p < 0.001), no difference by strain 
 Fetal liver hepcidin: mRNA hepcidin expression higher in 
Wistar compared to Rowett Hooded Lister (43%, p < 0.001), 
and was decreased by exposure to low iron diet in both strains 
(61%, p < 0.001) 
Sozo et al. 
(2013) [62] 
  n = 13 
 Animal: Border-Leicester × Merino ewes 
 Groups:  
1. Ethanol 0.75 g/kg (n = 8), daily IV 
administration on day 95–133 of gestation 
(3rd trimester) 
2. Saline (n = 7) 
 Sample: fetal liver 
 Timing: gestational day 134 (term is 
~day 145) 
 Method: mRNA by real-time RT-PCR 
 Fetal liver hepcidin: Gene expression lower in ethanol-exposed 
liver (0.2 ± 0.1) compared to control (1 ± 0.2), p = 0.011 
Neves et al. 
(2010) [58] 
Prospective,  
cross sectional 
 n = 13 
 Animal: mice 
 Groups:  
1. C57BL/6 (B6), n = 6 
2. Hfe−/− knockout, n = 7 
 Age: one year old nulliparous and pluriparous 
(mean = 29 weaned pups per female) 
 Diet: fed standard diet with iron content  
of 312 mg/kg 
 Sample: female liver 
 Timing: 1 year old. For pluriparous 
group, the sample was collected on 
average 11 weeks after last delivery 
 Method: hepcidin 1 and 2 mRNA by 
real-time RT-PCR 
 Hepcidin 1 and 2: lower expression of hepatic hepcidin mRNA 
in pluriparous mice (of both genotypes) compared to 
nulliparous (p < 0.01) 
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Table 1. Cont. 
Author Design Sample Hepcidin Main Study Findings 
Animal Studies 
Gambling 
et al. 
(2009) [59] 
Experimental, 
correlational, 
prospective 
 n = 104 
 Animal: virgin Rowett Hooded Lister Rats  
 Groups:  
1. control group 
2. supplemented in 1st half of pregnancy, iron 
deficient in the 2nd half 
3. iron deficient diet for 1st half, 
supplemented 2nd half 
4. deficient diet throughout 
 Sample: maternal and fetal liver 
 Timing: fetuses delivered by C/S on 
day 21.5 of gestation, 
 Method: real time quantitative PCR 
from total RNA from liver 
 Maternal liver hepcidin: mRNA hepcidin expression decreased 
in iron deficient group (p < 0.001), hepcidin restored to near 
control levels by iron supplementation in the 2nd half but not 
1st half of pregnancy (p < 0.05) 
 Fetal liver hepcidin: Low in fetuses from iron deficient group  
(p < 0.001); fetal liver iron and maternal liver hepcidin  
(r2 = 0.59, p < 0.001); fetal liver iron and hepcidin expression 
in fetal liver (r2 = 0.47, p < 0.001) 
Millard  
et al. (2004) 
[60] 
Cross-sectional, 
Prospective 
 n = 4 per time point 
 Animal: Sprague-Dawley rats 
 Age: mated at 10–12 weeks, those not pregnant 
used as control 
 Diet: All fed standard rodent pellet diet  
(370 mg iron/kg) 
 Sample: maternal liver 
 Timing: 5 time points: 9, 15, 18, and 
21 days gestation, and 24–48 h PP 
 Method: hepatic samples by 
ribonuclease protection assay 
 Maternal hepatic hepcidin mRNA: Progressive decline through 
gestation down to 1.9% of the non-pregnant level on day 21  
(p < 0.05); Postpartum levels normalized 
Note: NDR = no data reported; BMI = body mass index; sTfR = soluble transferrin receptor; C/S = cesarean section; GDM = gestational diabetes mellitus; IQR = interquartile range; PP = postpartum;  
CI = confidence interval; TIBC = total iron binding capacity; IL-6 = Interleukin-6; Hgb = hemoglobin level; CRP = C-reactive protein; EPO = erythropoietin; TfR index = transferring receptor index (TfR/log ferritin);  
AGP = alpha-1 acid glycoprotein; TBI = total body Fe; TfR = transferring receptor; HFE = Human hemochromatosis protein; sHJV = soluble hemojuvelin; AGP = α1-acid glycoprotein; Tsat = transferrin saturation;  
ns = not significant. 
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Six of the ten human studies utilized a cross-sectional study design [47–52] and four were 
longitudinal [53,55,56,68]. Sample size for the human studies ranged from 19 [52] to 191 subjects [48]. 
Human studies examined hepcidin values at 8 to 15 weeks gestation [49,55], 19 to 25 weeks [55], 24 to 
28 weeks gestation [56], 24 to 40 weeks gestation [50,55], at childbirth, [51,53], 24 h postpartum, [55] 
three days postpartum [53], and six weeks postpartum [55]. Only three studies examined hepcidin 
longitudinally across all three trimesters [55,68]. Cord blood hepcidin, obtained at delivery, was 
measured in four of the human studies [48,51,52,56]. Hepcidin was assessed in plasma [50,51],  
serum [48,52,53,55,56,68], and urine [47,49]. Seven of ten human studies analyzed hepcidin using 
mass spectrometry [47,49–51,53,55,68] and three studies used ELISAs [48,52,56]. Unfortunately, 
hepcidin values from the human studies cannot be directly compared to each other because hepcidin 
assays have not been standardized, and different methods yield different absolute values and normal 
ranges, although they correlate strongly [65]. It is unknown what magnitude of change in hepcidin 
value is biologically important during pregnancy. More research in larger populations is needed to 
determine the reference ranges for hepcidin during pregnancy. 
The six animal studies (performed on ewes, rats, and mice) were longitudinal. In rodents, sample 
collection ranged from 9 day to 21.5 days of gestation, and 24–48 h post-delivery [59,60]. In ewes, the 
samples were collected during the third trimester. Five of the six animal studies measured hepatic 
hepcidin mRNA expression. 
3.1. Maternal Hepcidin Levels through Pregnancy 
Hepcidin in pregnant women is lower than in nonpregnant healthy women and hepcidin levels 
decrease as pregnancy progresses, with the lowest hepcidin levels observed in the third trimester 
(longitudinal studies, and those assessing the third trimester) [53–56]. The increased need for fetal iron 
in the third trimester may be responsible for the decrease in maternal hepcidin observed, as fetal 
demand for iron is greatest in the third trimester [69]. The signals that suppress maternal hepcidin 
during pregnancy are unknown. Pregnancy-specific regulators of hepcidin production may exist, or 
hepcidin may be suppressed in response to decreasing maternal iron levels during pregnancy. 
Similarly, in animal studies liver hepcidin mRNA expression decreased throughout pregnancy.  
By day 21 in rodents (equivalent to the third trimester) hepcidin mRNA expression was 1.9% of  
non-pregnant values. However, hepcidin expression returned to pre-pregnancy concentrations within 
24 to 48 h postpartum (p < 0.05) [60], possibly because of the stress response associated with delivery 
and/or the loss of unknown inhibitory signals produced during pregnancy. Rats fed a low iron diet had 
lower levels of both maternal and fetal mRNA hepcidin expression compared to the control group [61]. 
This is likely a result of hepcidin suppression in iron deficient states, allowing for more bioavailable 
iron to be used by the system. So far, animal and human studies observed similar decreases in hepcidin 
during pregnancy. In general, the hepcidin regulatory circuitries have been shown to be very similar 
between rodents and humans, but it remains to be determined if any pregnancy-related differences  
may exist. 
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3.2. Maternal Hepcidin and Iron Status 
Maternal hepcidin concentrations were significantly correlated with indicators of maternal iron 
status [48,49,55]. During the first trimester of pregnancy, serum and urinary hepcidin were positively 
correlated with ferritin and negatively correlated with serum transferrin receptor (sTfR) index,  
a sensitive indicator of iron deficiency [49]. Similarly, throughout the gestational period, serum 
hepcidin correlated positively with ferritin and transferrin saturation and negatively with sTfR, and 
hemoglobin concentration [55]. This suggests that hepcidin regulation by iron and erythropoiesis is 
preserved in pregnancy [66]. Even at delivery (samples collected at admission), plasma hepcidin was 
associated with maternal hemoglobin, ferritin, total iron, and sTfR [52], and was found to be lowest in 
pregnant women with the poorest iron status [48]. However, one to three days postpartum, serum 
hepcidin levels increased, and did not correlate with serum iron or ferritin, likely due to the transient 
effect of the stress of delivery [51,53,55]. 
Hepcidin was reduced in women with low circulating iron and elevated erythropoiesis [48]. True iron 
deficiency anemia is defined by both lower ferritin values (<30 ng/mL) and hemoglobin (<12 g/dL) [70]. 
Further research with larger sample sizes and longitudinal designs are needed to determine how 
hepcidin changes throughout each trimester of pregnancy in relationship to iron status parameters. 
Iron deficiency decreased the mRNA expression of hepcidin in the animal studies similar to what 
was been observed in non-pregnant populations [37]. Rat mothers that were fed an iron deficient diet 
had lower hepcidin values [59]. Their hepcidin was significantly higher at 21.5 days if iron was 
supplemented in the second half of pregnancy, but not if supplemented in the first half [59].  
Hepatic hepcidin mRNA expression was also lower in pluriparous mice compared to nulliparious 
mice, when hepcidin was assessed after the last delivery, suggesting that pluriparous mice had greater 
iron transfer to the pups [58]. 
3.3. Maternal Hepcidin and Inflammation 
In general, for uncomplicated pregnancies, hepcidin levels did not correlate with inflammatory 
markers during gestation [49,55]. However, one study found a positive correlation between the 
inflammatory marker C-reactive protein (CRP) and serum hepcidin at time of delivery (gestational age 
37–42 weeks) [48]. In high-risk pregnancies, such as those associated with inflammatory conditions 
(e.g., obesity or preeclampsia), hepcidin was elevated compared to healthy pregnancies [50,56].  
In obese women during the second trimester, hepcidin was higher than in lean controls and correlated 
positively with maternal CRP [56]. In pregnant women with preeclampsia, plasma hepcidin, IL-6 and 
ferritin were all increased whereas mean corpuscular hemoglobin concentrations were decreased 
compared to healthy pregnant women [50]. This is not surprising given that inflammation is a known 
regulator of hepcidin production [71] and preeclampsia is an inflammatory state during pregnancy. 
Elevated maternal hepcidin during pregnancy would be expected to cause iron restriction and diminish 
iron availability for placental transfer. How this affects placental and fetal development is not known. 
Two studies assessed hepcidin values in relationship with placental malaria [47,51]. Howard and 
colleges found that urinary hepcidin was positively associated with log parasitemia but not associated 
with hemoglobin or anemia [47]. Van Santen and colleges found no difference in hepcidin values 
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across malaria and anemia groups [51], but this population also had no significant difference in other 
parameters, including serum iron, ferritin, CRP or sTfR. 
3.4. Hepcidin and Delivery Type 
Hepcidin expression was analyzed in relationship to the types of delivery and the time of sample 
collection in two studies [48,53]. Significantly higher hepcidin values (samples drawn < 24 h before 
delivery) were found in women who delivered vaginally or by emergency cesarean section compared 
to those who delivered by elective cesarean section [48]. Active labor is physiologically and 
psychologically stressful and may cause the release of cytokines such as IL-6 and stress hormones [48], 
that may increase hepcidin expression. This would help to explain the higher hepcidin values observed 
at the time of delivery for emergency cesarean section versus elective cesarean section, where labor 
had not begun. However, another study did not find differences in hepcidin between those women 
delivering vaginally and those undergoing an elective cesarean section when the sample was drawn 
before delivery [53], but in both of these groups, hepcidin values increased at three days postpartum 
(three-fold for vaginal delivery and five-fold for elective cesarean section) [53]. The postpartum 
increase in hepcidin may be related to several factors including the stress of delivery and/or the 
cessation of any potential suppressive signal related to the pregnancy. At three days postpartum, 
women with elective cesarean section had higher hepcidin than those with vaginal delivery, in contrast 
to the hepcidin measurements pre-delivery [48]. In this case, the recovery from surgery may be 
associated with more prolonged inflammation than vaginal delivery, thus stimulating hepcidin 
production. Abdominal surgeries such as gastrectomy, colectomy, hepatectomy, and surgery for 
diffuse peritonitis have been reported to be associated with increased hepcidin values during the 
postoperative period [72]. This could have adverse health consequences for the recovery of mothers 
undergoing a cesarean section. 
3.5. Relationship between Maternal and Neonate Cord Blood Hepcidin and Iron Status 
Fetal hepcidin could regulate iron transport across placenta by controlling ferroportin levels in 
syncytiotrophoblast. However, the relative contribution of maternal versus fetal hepcidin in the 
regulation of placental iron transport during pregnancy is unknown. Four human studies examined 
maternal hepcidin compared to cord blood hepcidin values drawn at delivery [48,51,52,56] and found 
significantly lower hepcidin in maternal serum compared to cord blood samples [48,51,52].  
Lower maternal hepcidin values during pregnancy would ensure maximal iron transport to the fetus [48]. 
Cord blood hepcidin was associated with cord blood iron status [48], but no correlation was detected 
between maternal and cord blood hepcidin in any of the studies. However, in two studies, maternal 
hepcidin correlated with newborn cord blood iron status parameters [52]. In obese women, maternal 
hepcidin correlated negatively with newborn cord blood serum iron and transferrin saturation [56].  
In a study examining maternal absorption and placental transfer of isotopically-labeled non-heme and 
heme iron, the transfer of iron to the fetus inversely correlated with maternal hepcidin (non-heme 57Fe 
p = 0.002, r2 = 0.43; heme 58Fe p = 0.004, r2 = 0.39) and was directly associated with neonatal 
hemoglobin (p = 0.004, r2 = 0.39; p = 0.008, r2 = 0.35) [52]. These findings indicate that maternal 
hepcidin at least in part determines fetal iron homeostasis. 
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In animal studies, fetal hepcidin expression correlated with their iron status. In rat studies [59], fetal 
hepcidin at 21.5 days was the lowest when mothers where fed an iron deficient diet throughout the 
pregnancy, moderate correction of hepcidin levels was observed if iron was supplemented in the first 
half of pregnancy, and complete correction of fetal hepcidin levels were observed if iron was 
supplemented in the second half of pregnancy [59]. 
4. Limitations 
There are limitations to the review that warrant discussion. The small number of research studies 
that assess hepcidin during pregnancy limits the strength of the conclusions. The sample sizes of most 
individual studies were small and future research should assess hepcidin in large population studies of 
pregnant women. While the hepcidin measurements obtained by different methods such as ELISA and 
mass spectroscopy correlate well [73], the absolute hepcidin values are substantially different depending 
on the method and cannot be related to one another, limiting comparisons across studies. 
Harmonization of different hepcidin methods is needed to allow establishment of a consistent reference 
range across different stages of pregnancy. 
The cross-sectional study design of most human studies limited our ability to draw conclusions 
about changes in hepcidin values throughout the pregnancy. Furthermore, very little is known about 
hepcidin in complicated pregnancies. Only one study examined hepcidin values in patients diagnosed 
with preeclampsia [50], one in obese versus lean women [56], and two studies examined hepcidin 
values in patients infected with malaria [47,51]. Future research should examine hepcidin values in 
relationship to other pregnancy complications, such as preterm birth and low birth weight. Increase in 
blood volume in pregnancy could in itself cause the decrease in hepcidin concentrations in blood.  
For example, albumin concentration decreases to about 80% of the non-pregnant levels [74]. However, 
hepcidin decrease in the third trimester is much greater suggesting that hepcidin decrease cannot be 
explained solely by changes in blood volume. 
5. Conclusions 
Hepcidin is a regulator of iron homeostasis and may be a useful biomarker to determine iron 
bioavailability in pregnancy. Proper diagnosis of true iron deficiency anemia versus inflammation-mediated 
iron restriction during pregnancy may help clinicians prescribe iron therapy appropriately. Treating the 
underlying disease and/or use of erythropoietic agents may be an appropriate alternative [70].  
Future research is needed to examine the association between hepcidin values in pregnancy and pregnancy 
complications. Research examining early pregnancy hepcidin values is needed as elevated or very low 
hepcidin values could be used as an early diagnostic indicator of maternal iron bioavailability. 
Both maternal and fetal hepcidin may determine the degree of placental iron transfer. Fetal-derived 
hepcidin may play a role in the regulation of Fpn expressed at the basolateral side of the 
syncytiotrophoblast [31] and determine the rate of iron entry into fetal circulation [35]. In fact, 
transgenic mice engineered to overexpress hepcidin during embryonic development spontaneously 
aborted in utero due to severe iron deficiency [57]. Maternal hepcidin, however, would regulate Fe-Tf 
concentrations in maternal circulation by dictating the flux of iron coming from the diet as well as 
storage sites, and this would determine the amount of iron presented to the placenta for uptake. 
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Throughout pregnancy, accommodation for increased iron needs for both the mother and fetus are 
supported by a substantial increase in maternal dietary iron absorption, and increased iron flux to the 
fetus via the Fpn-rich placenta. One would expect markedly low maternal hepcidin concentrations to 
accommodate this transfer [5,75]. In conditions which infection or inflammation is present, maternal 
iron bioavailability could be significantly reduced limiting the amount of iron presented for uptake by 
the placenta and for transfer to the fetus. Future studies should examine the direct and indirect effects 
of maternal and fetal hepcidin on placental expression of iron management proteins. It remains to be 
determined if elevated hepcidin during pregnancy is a pathogenic factor adversely impacting maternal 
and fetal outcomes. 
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